[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Alzheimer’s Drug Market: Trends, Opportunities and Forecasts (2015-2020) (By Type - Imaging, Therapeutics, Diagnostics, Biomarkers; By Age: <65 years, >65 years age; By Region; Global Dementia Market)

December 2015 | 106 pages | ID: G9E15680E71EN
Azoth Analytics

US$ 2,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Executive Summary

Progressive numbers of neurological disorders along with escalating demand for drugs to control of Alzheimer Disease.

The Global Alzheimer’s Market is growing at a moderate rate over last five years on account of rising expenditure on health care especially neurological disorders among ageing population and escalating role of private and government bodies in empowering R&D measures to avoid degenerative disorders. During 2015-20, Global Alzheimer Disease Market is anticipated to grow at an increased rate on account of robust expansion plans of the increase in medical facilities. Moreover, increase in number of patients suffering from degenerative disorder is further anticipated to boost the Global Alzheimer’s market in the coming years.

According to Azoth Analytics research report, “Global Alzheimer’s Drug Market: Trends, Opportunities and Forecasts (2015-2020) - (By Type - Imaging, Therapeutics, Diagnostics, Biomarkers; By Age: 65 years, 65 years; By Region; Global Dementia Market)”, global Alzheimer’s market is projected to exhibit a CAGR of over 8.54% during 2015–2020. On the basis of Reisberg Scale, market is categorized by seven stages of Alzheimer. Alzheimer is expected to be cured by Drugs; Exercise and Nutrition. Growth in Alzheimer’s Drug market is anticipated to grow in the next five years. Asia Pacific region dominated the revenue contribution share in 2014 and the region is forecast to continue its domination through 2020. Few of the leading companies operating in Global Alzheimer’s Disease Market include Axovant Sciences Ltd., Biotie Therapies, Acadia Pharmaceuticals, Novartis International AG and many more.

Scope of the Report

The report “Global Alzheimer’s Drug Market: Trends, Opportunities and Forecasts (2015-2020) - (By Type - Imaging, Therapeutics, Diagnostics, Biomarkers; By Age: 65 years, 65 years; By Region; Global Dementia Market)” analyzes the following aspects of global Alzheimer’s market:
  • Global Alzheimer’s Market Size, Share & Forecast
  • Segmental Analysis – By Therapeutics, By Diagnostics and Biomarkers, By Imaging Sector, By Patient and By Drugs
  • Policy & Regulatory Landscape
  • Market Entry Strategies for Domestic/Foreign Players
  • Changing Market Trends & Emerging Opportunities
  • Competitive Landscape & Strategic Recommendations
Why You Should Buy This Report?

1. To gain an in-depth understanding of Alzheimer disease and dementia market propelling globally.
2. To identify the on-going trends and anticipated growth in the next five years
3. To help industry consultants, drug and diagnostics manufacturers, vendors and dealers align their market-centric strategies
4. To obtain research based business decision and add weight to presentations and marketing material
5. To gain competitive knowledge of leading players
6. To avail limited customization in the report without any extra charges and get research data or trends added in the report as per the buyer’s specific needs
1. RESEARCH METHODOLOGY

2. ALZHEIMER’S DISEASE MARKET OVERVIEW

3. GLOBAL ALZHEIMER’S DISEASE MARKET OUTLOOK

4. GLOBAL ALZHEIMER’S DISEASE MARKET

4.1 By Therapeutics
4.2 By Diagnostics and Biomarkers
4.3 By Imaging Sector
4.4 By Disease Modifying Therapeutics

5. GLOBAL ALZHEIMER’S DISEASE MARKET OUTLOOK-BY DEMOGRAPHIC (AGE-GROUP)

6. GLOBAL ALZHEIMER’S DISEASE MARKET OUTLOOK-BY DRUG

7. GLOBAL ALZHEIMER’S DISEASE MARKET OUTLOOK-BY REGION

8. UNITED STATES ALZHEIMER’S DISEASE MARKET OUTLOOK

8.1 United States Dementia Market Outlook

9. GLOBAL DEMENTIA DISEASE MARKET OUTLOOK

10. GLOBAL DEMENTIA DISEASE MARKET OUTLOOK

10.1 By Regional Break-Up
  10.1.1 Asia-Pacific Dementia Market Outlook
10.2 By Countries
  10.2.1 Low Income Country -wise Break up
  10.2.2 Top Ten Country-wise Break-Up
    Australia Dementia Market Outlook
    UK Dementia Market Outlook

11. MARKET DYNAMICS

11.1 Drivers
11.2 Challenges

12. MARKET TRENDS & DEVELOPMENTS

13. COMPETITIVE LANDSCAPE

13.1 Sales Comparatives, Top 5 Companies
13.2 EBITDA Comparatives, Top 5 Companies
13.3 EBIT Comparatives, Top 5 Companies
13.4 PBT Comparatives, Top 5 Companies
13.5 PAT Comparatives, Top 5 Companies
13.6 Current Ratio Comparatives, Top 5 Companies

14. COMPANY PROFILING

14.1 Pfizer Inc.
14.2 Novartis International AG
14.3 Axovant Sciences Ltd.
14.4 Acadia Pharmaceuticals
14.5 Biotie Therapies

LIST OF FIGURES

Figure 1. Global Alzheimer’s Disease Market Size, By Value (USD Billion) and Volume (Number of Patients in Million) 2010-2020F
Figure 2. Global Alzheimer’s Disease Market by Therapeutics, By Value (USD Million) 2010-2020F
Figure 3. Global Alzheimer’s Market share, By Therapeutics
Figure 4. Global Alzheimer’s Disease Market, By Diagnostics and Biomarkers, By Value (USD Billion)
Figure 5. Global Alzheimer’s Disease Market, By Imaging Sector, By Value (USD Million)
Figure 6. Global Alzheimer’s Disease Market by Disease Modifying Therapeutics Market Size, By Value (USD Million)
Figure 7. Global Alzheimer’s Disease Market, By Demographics, By Age 65, By Volume (Number of patients in million), 2010-2020F
Figure 8. Global Alzheimer’s Disease Market, By Demographics, By Age 65, By Volume (Number of patients in million), 2010-2020F
Figure 9. Global Memantine (Nameda) Drug Market Size, By Value (USD Billion) and Volume (Number of Patients in Million) 2010-2020F
Figure 10. United States Dementia Disease Market Size, By Value (USD Million) and Volume (Number of Patients In Million) 2010-2020F
Figure 11. Cost of Alzheimer Disease in United States, By Payer, By percentage, 2010-14
Figure 12. U.S. Alzheimer’s Drug RTV-101 Market, By Value & Penetration Rate; 2019-2027 (USD Million)
Figure 13. U.S. Alzheimer’s Drug Azeliragon Market, By Value & Penetration Rate, 2019-2027 (USD Million)
Figure 14. U.S. Annual Alzheimer’s Death Rates, By Age; 2006-2013
Figure 15. U.S. Annual Alzheimer’s Death Rates, By Age; 2006-2013
Figure 16. Global Dementia Disease Market Size, By Value (USD Million) and Volume (Number of Patients In Million) 2010-2020F
Figure 17. Global Dementia Disease Market Size, By Volume (Number of Patients In Million), By Region 2014
Figure 18. Global Dementia Disease Market Size, By Number of new cases, By Volume (Number of Patients In Million), By Region 2014
Figure 19. Asia-Pacific Dementia Disease Market Size, By Volume (Number of Patients In Million), By country 2015E, 2030F, 2050F
Figure 20. Global Dementia Disease Market Size, By Volume (Number of Patients In Million), By Region 2014
Figure 21. Global Dementia Disease Market Size Low Income Countries, Volume (Number of Patients In Million) 2010-2020F
Figure 22. Global Dementia Disease Market Size Low Income Countries, Volume (Number of Patients In Million) 2010-2020F
Figure 23. Global Dementia Disease Market Size in Top Ten Countries, Volume (Number of Patients In Million) 2010-2020F
Figure 24. Australia Dementia Disease Market Size, By Volume (Number of Patients In Million) 2010-2020F
Figure 25. Australia Dementia Disease Market Size, By Volume (Number of Patients In Million) 2010-2020F
Figure 26. UK Dementia Market, By Type, 2014 (%)
Figure 27. UK Dementia Cost, By Type of Service, 2014 (%)
Figure 28. Number of Unpaid Caregivers (In Million)
Figure 29. Pfizer Revenue (USD Million) AY 2011-2014
Figure 30. Axovant Services Ltd. Revenue (USD Million) FY 2011-2015
Figure 31. Pfizer Percentage Revenue, By Business Segment (2014)
Figure 32. Pfizer Percentage Revenue, By Geography (2014)
Figure 33. Novartis International AG Revenue (USD Million) AY 2011-2014
Figure 34. Novartis International AG Percentage Revenue, By Business Segment (2014)
Figure 35. Novartis International AG Percentage Revenue, By Geography (2014)
Figure 36. Axovant Services Ltd. Revenue (USD Million) FY 2011-2015
Figure 37. Axovant Services Ltd. Percentage Revenue, By Business Segment (2014)
Figure 38. Axovant Services Ltd. Percentage Revenue, By Geography (2014)
Figure 39. Acadia Pharmaceuticals Revenue (USD Million) AY 2011-2014
Figure 40. Acadia Pharmaceuticals Percentage Revenue, By Business Segment (2014)
Figure 41. Acadia Pharmaceuticals Percentage Revenue, By Geography (2014)
Figure 42. Biotie Therapies Revenue (USD Million) AY 2011-2014
Figure 43. Biotie Therapies Percentage Revenue, By Business Segment (2014)
Figure 44. Sales Comparatives, Top 5 Companies, 2011-2014
Figure 45. EBITDA Comparatives, Top 5 Companies, 2011-2015
Figure 46. EBIT Comparatives, Top 5 Companies, 2011-2015
Figure 47. PBT Comparatives, Top 5 Companies, 2011-2015
Figure 48. PAT Comparatives, Top 5 Companies, 2011-2015
Figure 49. Current Ratio Comparatives, Top 5 Companies, 2011-2015
Figure 50. Profit Margin Ratio Comparatives, Top 5 Companies, 2011-2015
Figure 51. Debt Equity Ratio Comparatives, Top 5 Companies, 2011-2015


More Publications